Deciphering the genetic basis of developmental language disorder in children without intellectual disability, autism or apraxia of speech / Marion LESIEUR-SEBELLIN ; Karine SIQUIER-PERNET ; Geoffroy DELPLANCQ ; Marlene RIO ; Mélanie PARISOT ; Patrick NITSCHKÉ ; Cristina RODRIGUEZ-FONTENLA ; Alison BODINEAU ; Lucie NARCY ; Emilie SCHLUMBERGER ; Vincent CANTAGREL ; Valérie MALAN in Molecular Autism, 16 (2025)  

Public ISBD [article]  inMolecular Autism > 16 (2025) . - 10 p. Titre : Deciphering the genetic basis of developmental language disorder in children without intellectual disability, autism or apraxia of speech Type de document : texte imprimé Auteurs : Marion LESIEUR-SEBELLIN, Auteur ; Karine SIQUIER-PERNET, Auteur ; Geoffroy DELPLANCQ, Auteur ; Marlene RIO, Auteur ; Mélanie PARISOT, Auteur ; Patrick NITSCHKÉ, Auteur ; Cristina RODRIGUEZ-FONTENLA, Auteur ; Alison BODINEAU, Auteur ; Lucie NARCY, Auteur ; Emilie SCHLUMBERGER, Auteur ; Vincent CANTAGREL, Auteur ; Valérie MALAN, Auteur Article en page(s) : 10 p. Langues : Anglais (eng) Mots-clés : Humans  Male  Female  Child  Language Development Disorders/genetics  Apraxias/genetics  Child, Preschool  Intellectual Disability/genetics  DNA Copy Number Variations  Adolescent  Genetic Predisposition to Disease  15q13.3 locus  16p11.2 locus  Autism  Developmental language disorder  Intellectual disability  Neurodevelopmental disorders  ZNF292  use the data for research and publication purposes. Competing interests: The  authors declare no competing interests. Ethics approval and consent to  participate: Written informed consent was obtained from all individuals. All  studies were carried out in accordance with the declaration of Helsinki and were  approved by a national ethics committee (CPP Ile de France, RIPH2G reference DI  24.01180.000212, N°2024-A00519-38, CPP reference 29-2024, promoter reference  C23-79  promoter: Inserm). ClinicalTrials.gov Identifier: NCT06660108. Index. décimale : PER Périodiques Résumé : BACKGROUND: Developmental language disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability (ID). The clinical heterogeneity of language disorders, the frequent presence of comorbidities, and the inconsistent terminology used over the years have impeded both research and clinical practice. Identifying sub-groups of children (i.e. DLD cases without childhood apraxia of speech (CAS)) with language difficulties is essential for elucidating the underlying genetic causes of this condition. DLD presents along a spectrum of severity, ranging from mild speech delays to profound disturbances in oral language structure in otherwise typically intelligent children. The prevalence of DLD is ~ 7-8% or 2% if severe forms are considered. This study aims to investigate a homogeneous cohort of DLD patients, excluding cases of ASD, ID or CAS, using multiple genomic approaches to better define the molecular basis of the disorder. METHODS: Fifteen families, including 27 children with severe DLD, were enrolled. The majority of cases (n = 24) were included in multiplex families while three cases were sporadic. This resulted in a cohort of 59 individuals for whom chromosomal microarray analysis and exome or genome sequencing were performed. RESULTS: We identified copy number variants (CNVs) predisposing to neurodevelopmental disorders with incomplete penetrance and variable expressivity in two families. These CNVs (i.e., 15q13.3 deletion and proximal 16p11.2 duplication) are interpreted as pathogenic. In one sporadic case, a de novo pathogenic variant in the ZNF292 gene, known to be associated with ID, was detected, broadening the spectrum of this syndrome. LIMITATIONS: The strict diagnostic criteria applied by our multidisciplinary team, including speech-language physicians, neuropsychologists, and paediatric neurologists, resulted in a relatively small sample size, which limit the strength of our findings. CONCLUSION: These findings highlight a common genetic architecture between DLD, ASD and ID, and underline the need for further investigation into overlapping neurodevelopmental pathways. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06660108. En ligne : https://dx.doi.org/10.1186/s13229-025-00642-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=555 [article] Deciphering the genetic basis of developmental language disorder in children without intellectual disability, autism or apraxia of speech [texte imprimé] / Marion LESIEUR-SEBELLIN, Auteur ; Karine SIQUIER-PERNET, Auteur ; Geoffroy DELPLANCQ, Auteur ; Marlene RIO, Auteur ; Mélanie PARISOT, Auteur ; Patrick NITSCHKÉ, Auteur ; Cristina RODRIGUEZ-FONTENLA, Auteur ; Alison BODINEAU, Auteur ; Lucie NARCY, Auteur ; Emilie SCHLUMBERGER, Auteur ; Vincent CANTAGREL, Auteur ; Valérie MALAN, Auteur . - 10 p. Langues : Anglais (eng) in Molecular Autism > 16 (2025) . - 10 p. Mots-clés : Humans  Male  Female  Child  Language Development Disorders/genetics  Apraxias/genetics  Child, Preschool  Intellectual Disability/genetics  DNA Copy Number Variations  Adolescent  Genetic Predisposition to Disease  15q13.3 locus  16p11.2 locus  Autism  Developmental language disorder  Intellectual disability  Neurodevelopmental disorders  ZNF292  use the data for research and publication purposes. Competing interests: The  authors declare no competing interests. Ethics approval and consent to  participate: Written informed consent was obtained from all individuals. All  studies were carried out in accordance with the declaration of Helsinki and were  approved by a national ethics committee (CPP Ile de France, RIPH2G reference DI  24.01180.000212, N°2024-A00519-38, CPP reference 29-2024, promoter reference  C23-79  promoter: Inserm). ClinicalTrials.gov Identifier: NCT06660108. Index. décimale : PER Périodiques Résumé : BACKGROUND: Developmental language disorder (DLD) refers to children who present with language difficulties that are not due to a known biomedical condition or associated with autism spectrum disorder (ASD) or intellectual disability (ID). The clinical heterogeneity of language disorders, the frequent presence of comorbidities, and the inconsistent terminology used over the years have impeded both research and clinical practice. Identifying sub-groups of children (i.e. DLD cases without childhood apraxia of speech (CAS)) with language difficulties is essential for elucidating the underlying genetic causes of this condition. DLD presents along a spectrum of severity, ranging from mild speech delays to profound disturbances in oral language structure in otherwise typically intelligent children. The prevalence of DLD is ~ 7-8% or 2% if severe forms are considered. This study aims to investigate a homogeneous cohort of DLD patients, excluding cases of ASD, ID or CAS, using multiple genomic approaches to better define the molecular basis of the disorder. METHODS: Fifteen families, including 27 children with severe DLD, were enrolled. The majority of cases (n = 24) were included in multiplex families while three cases were sporadic. This resulted in a cohort of 59 individuals for whom chromosomal microarray analysis and exome or genome sequencing were performed. RESULTS: We identified copy number variants (CNVs) predisposing to neurodevelopmental disorders with incomplete penetrance and variable expressivity in two families. These CNVs (i.e., 15q13.3 deletion and proximal 16p11.2 duplication) are interpreted as pathogenic. In one sporadic case, a de novo pathogenic variant in the ZNF292 gene, known to be associated with ID, was detected, broadening the spectrum of this syndrome. LIMITATIONS: The strict diagnostic criteria applied by our multidisciplinary team, including speech-language physicians, neuropsychologists, and paediatric neurologists, resulted in a relatively small sample size, which limit the strength of our findings. CONCLUSION: These findings highlight a common genetic architecture between DLD, ASD and ID, and underline the need for further investigation into overlapping neurodevelopmental pathways. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06660108. En ligne : https://dx.doi.org/10.1186/s13229-025-00642-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=555

Impact of on-site clinical genetics consultations on diagnostic rate in children and young adults with autism spectrum disorder / Arnold MUNNICH in Molecular Autism, 10 (2019)  

Public ISBD [article]  inMolecular Autism > 10 (2019) . - 33 p. Titre : Impact of on-site clinical genetics consultations on diagnostic rate in children and young adults with autism spectrum disorder Type de document : texte imprimé Auteurs : Arnold MUNNICH, Auteur ; Caroline DEMILY, Auteur ; L. FRUGERE, Auteur ; Charlyne DUWIME, Auteur ; Valérie MALAN, Auteur ; Giulia BARCIA, Auteur ; Céline VIDAL, Auteur ; Emeline THROO, Auteur ; Claude BESMOND, Auteur ; Laurence HUBERT, Auteur ; Gilles ROLAND-MANUEL, Auteur ; Jean-Pierre MALEN, Auteur ; Mélanie FERRERI, Auteur ; Sylvain HANEIN, Auteur ; Jean-Christophe THALABARD, Auteur ; Nathalie BODDAERT, Auteur ; Moïse ASSOULINE, Auteur Article en page(s) : 33 p. Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Copy number variant  Fragile X syndrome  Gene panel  Genetic counseling  Genetic diagnosis  Microarray  Next-generation sequencing  Sequence variant Index. décimale : PER Périodiques Résumé : Background: Neurogenetics investigations and diagnostic yield in patients with autism spectrum disorder (ASD) have significantly improved over the last few years. Yet, many patients still fail to be systematically investigated. Methods: To improve access to services, an ambulatory team has been established since 1998, delivering on-site clinical genetics consultations and gradually upgrading services to 502 children and young adults with ASD in their standard environment across 26 day-care hospitals and specialized institutions within the Greater Paris region. The evaluation included a clinical genetics consultation, screening for fragile X syndrome, metabolic workup, chromosomal microarray analysis, and, in a proportion of patients, next-generation sequencing of genes reported in ASD and other neurodevelopmental disorders. Results: Fragile X syndrome and pathogenic copy number variants (CNVs) accounted for the disease in 10% of cases, including 4/312 (1.3%) with fragile X syndrome and 34/388 (8.8%) with pathogenic CNVs (19 de novo and 4 inherited). Importantly, adding high-throughput resequencing of reported intellectual disability/ASD genes to the screening procedure had a major impact on diagnostic yield in the 141 patients examined most recently. Pathogenic or likely pathogenic sequence variants in 27 disease genes were identified in 33/141 patients (23.4%; 23 were de novo and 10 inherited, including five X-linked and five recessive compound heterozygous variants). Diagnosed cases presented atypical and/or syndromic ASD with moderate to severe intellectual disability. The diagnostic yield of fragile X syndrome and array CGH testing combined with next-generation sequencing was significantly higher than fragile X syndrome and array CGH alone (p value 0.009). No inborn errors of metabolism were detected with the metabolic screening. Conclusion: Based on the diagnostic rate observed in this cohort, we suggest that a stepwise procedure be considered, first screening pathogenic CNVs and a limited number of disease genes in a much larger number of patients, especially those with syndromic ASD and intellectual disability. En ligne : https://dx.doi.org/10.1186/s13229-019-0284-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=408 [article] Impact of on-site clinical genetics consultations on diagnostic rate in children and young adults with autism spectrum disorder [texte imprimé] / Arnold MUNNICH, Auteur ; Caroline DEMILY, Auteur ; L. FRUGERE, Auteur ; Charlyne DUWIME, Auteur ; Valérie MALAN, Auteur ; Giulia BARCIA, Auteur ; Céline VIDAL, Auteur ; Emeline THROO, Auteur ; Claude BESMOND, Auteur ; Laurence HUBERT, Auteur ; Gilles ROLAND-MANUEL, Auteur ; Jean-Pierre MALEN, Auteur ; Mélanie FERRERI, Auteur ; Sylvain HANEIN, Auteur ; Jean-Christophe THALABARD, Auteur ; Nathalie BODDAERT, Auteur ; Moïse ASSOULINE, Auteur . - 33 p. Langues : Anglais (eng) in Molecular Autism > 10 (2019) . - 33 p. Mots-clés : Autism spectrum disorder  Copy number variant  Fragile X syndrome  Gene panel  Genetic counseling  Genetic diagnosis  Microarray  Next-generation sequencing  Sequence variant Index. décimale : PER Périodiques Résumé : Background: Neurogenetics investigations and diagnostic yield in patients with autism spectrum disorder (ASD) have significantly improved over the last few years. Yet, many patients still fail to be systematically investigated. Methods: To improve access to services, an ambulatory team has been established since 1998, delivering on-site clinical genetics consultations and gradually upgrading services to 502 children and young adults with ASD in their standard environment across 26 day-care hospitals and specialized institutions within the Greater Paris region. The evaluation included a clinical genetics consultation, screening for fragile X syndrome, metabolic workup, chromosomal microarray analysis, and, in a proportion of patients, next-generation sequencing of genes reported in ASD and other neurodevelopmental disorders. Results: Fragile X syndrome and pathogenic copy number variants (CNVs) accounted for the disease in 10% of cases, including 4/312 (1.3%) with fragile X syndrome and 34/388 (8.8%) with pathogenic CNVs (19 de novo and 4 inherited). Importantly, adding high-throughput resequencing of reported intellectual disability/ASD genes to the screening procedure had a major impact on diagnostic yield in the 141 patients examined most recently. Pathogenic or likely pathogenic sequence variants in 27 disease genes were identified in 33/141 patients (23.4%; 23 were de novo and 10 inherited, including five X-linked and five recessive compound heterozygous variants). Diagnosed cases presented atypical and/or syndromic ASD with moderate to severe intellectual disability. The diagnostic yield of fragile X syndrome and array CGH testing combined with next-generation sequencing was significantly higher than fragile X syndrome and array CGH alone (p value 0.009). No inborn errors of metabolism were detected with the metabolic screening. Conclusion: Based on the diagnostic rate observed in this cohort, we suggest that a stepwise procedure be considered, first screening pathogenic CNVs and a limited number of disease genes in a much larger number of patients, especially those with syndromic ASD and intellectual disability. En ligne : https://dx.doi.org/10.1186/s13229-019-0284-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=408

---

1 (1 - 2 / 2) Par page : 25 50 100 200